found Documents: 429

Announcements & Press Releases, Oncology / Immunology | 5 Jun 2025

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, June 5, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Appl

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 2 Jun 2025

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

2 items

— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study — — Webcast to be held at 8:30 am HKT on Tuesday, June 3 t

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 23 May 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, May 23, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitini

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 24 Apr 2025

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, April 24, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED incl

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 22 Apr 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, April 22, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savo

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 21 Mar 2025

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK^® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

2 items

— First and only EZH2 inhibitor approved by the NMPA — —HUTCHMED’s fourth product, and its first approval in hematological malignancies — Hong Kong, Shanghai & Florham Park, NJ — Friday, March 21, 2025: HUTCHMED (C

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 20 Mar 2025

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

2 items

— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 19 Mar 2025

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

2 items

65% oncology products revenue growth drove profitable operation and supported new ATTC platform Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we�

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 19 Mar 2025

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jointly announce that the FRUSICA-2

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 6 Mar 2025

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, March 6, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of its a Phase II trial of fanregratinib (HMPL-453)

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group, Regulatory Notice | 19 Feb 2025

HUTCHMED to Announce 2024 Final Results

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2024 on Wednesday, March 19, 2025 a

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 14 Jan 2025

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

2 items

— Indication expands to include treatment-naïve patients — — The 2021 conditional approval in previously treated patients converted to full approval — Hong Kong, Shanghai & Florham Park, NJ — Tuesday, January 14, 2025: HUTCH

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 2 Jan 2025

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS^® and TAGRISSO^® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, January 2, 2025: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) a

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 1 Jan 2025

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

1 item

— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED’s pipeline and core innovat

LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 13 Dec 2024

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA^® (fruquintinib)

2 items

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cance

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 12 Dec 2024

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS^® and TAGRISSO^® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, December 12, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the Center for Drug Evaluation of China’s National Medical Products Administration

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 3 Dec 2024

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE^® (Fruquintinib) in Combination with TYVYT^® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

2 items

— First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor — Hong Kong, Shanghai & Florham Park, NJ — Tuesday, December 3, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 28 Nov 2024

HUTCHMED Announces Continued Inclusion of ORPATHYS^® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, November 28, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Admi

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 22 Nov 2024

HUTCHMED Announces Launch by Takeda of FRUZAQLA^® (fruquintinib) in Japan

2 items

— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States,

LSE RNS Announcemnet (PDF)HKEX Annoucement (PDF)

Announcements & Press Releases, Oncology / Immunology | 6 Nov 2024

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, November 6, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as severa

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 31 Oct 2024

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA^® (fruquintinib) Sales by Takeda

2 items

— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer — Hong Kong, Shanghai & Florham Park, NJ — Thursday, October 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today a

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 16 Oct 2024

HUTCHMED Announces that TAGRISSO^® plus ORPATHYS^® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

2 items

— New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer — — MET is a common biomarker in this setting for patients who develop resistance to EGFR targeted therapies

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 3 Oct 2024

HUTCHMED’s ELUNATE^® (fruquintinib) Listed with Full Subsidy in the Hong Kong Hospital Authority Drug Formulary

1 item

— First innovative oncology medicine ever to get enlisted in HA Drug Formulary directly under the Special Drug category — — First new drug approved by 1+ Mechanism listed in the Hospital Authority Drug Formulary — — Rapid enlistment and

View Press Release (PDF)

Announcements & Press Releases, Oncology / Immunology | 24 Sep 2024

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

2 items

— Approval based on results from global Phase III FRESCO-2 trial in patients with previously treated metastatic colorectal cancer — — Fruquintinib already approved in several regions including the United States, Europe and China —

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 10 Sep 2024

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

2 items

Hong Kong, Shanghai & Florham Park, NJ — Monday, September 9, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be p

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 30 Aug 2024

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, August 30, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in C

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 21 Aug 2024

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, August 21, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert call with a professor and key opinion leader in immune

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Group | 31 Jul 2024

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, July 31, 2024: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, 20

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 4 Jul 2024

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, July 4, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of adult pat

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group, Regulatory Notice | 26 Jun 2024

HUTCHMED to Announce 2024 Half-Year Financial Results

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, June 26, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 24 Jun 2024

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

2 items

— HUTCHMED will host in-person presentation and online webinar on Tuesday, July 9 — Hong Kong, Shanghai & Florham Park, NJ — Monday, June 24, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today an

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 22 Jun 2024

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

2 items

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZAQLA® (fruquintinib) is the first novel targeted therapy in the EU for metastatic colorectal cancer regard

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 17 Jun 2024

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

2 items

— Publication shows treatment demonstrated durable response rate of 48.4% vs. 0% with placebo — — Presentations at EHA showcased subgroup analyses demonstrating consistent benefits regardless of prior lines of therapies or prior TPO/TPO-RA[1

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 7 Jun 2024

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, June 7, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hem

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 3 Jun 2024

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

2 items

Updated subgroup efficacy and quality of life data were also presented on June 1 at ASCO 2024 Hong Kong, Shanghai & Florham Park, NJ — Monday, June 3, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) to

HKEX Announcement (PDF)LSE RNS Announcemnet (PDF)

Announcements & Press Releases, Oncology / Immunology | 24 May 2024

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, May 24, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presen

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology, Press Releases | 17 May 2024

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, May 17, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that topline and subgroup results from the ESLIM‑01 Phase III study of sovleplenib, as well as

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcement Topics, Announcements & Press Releases, Oncology / Immunology, Press Releases | 14 May 2024

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

2 items

— Almost half a million people diagnosed each year across the globe — — Collaboration based on synergistic potential of inhibiting angiogenesis and tumor-associated macrophages with HUTCHMED’s surufatinib and anti-PD-1 activity with Hengr

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 14 May 2024

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, May 14, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mut

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 26 Apr 2024

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

2 items

— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO‑2 Phase III clinic

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 5 Apr 2024

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, April 5, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be prese

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 2 Apr 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

2 items

— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in combination with a leading immune checkpoint inhibito

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 28 Mar 2024

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

2 items

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would confirm 2021 conditional approval and exp

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 22 Mar 2024

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday, March 22, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated the registration stage of the Phase II/III clinical trial of sovleplenib

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group | 28 Feb 2024

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

2 items

Revenue grew 97% (102% CER) to US$838 million, with net income of US$101 million First U.S. FDA approval of our self-developed medicine, FRUZAQLA™ (fruquintinib) Sovleplenib for ITP accepted for NDA review in China, with Priority Review status an

LSE RNS Announcemnent (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 7 Feb 2024

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

2 items

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, February 7, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that data from FRUTIGA, HUTCHMED’s Phase III trial of fruquintinib in combination

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 2 Feb 2024

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

2 items

Hong Kong, Shanghai & Florham Park, NJ — Friday February 2, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announced that, Inmagene Biopharmaceuticals (“Inmagene”) has exercised options to license two

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Group, Regulatory Notice | 1 Feb 2024

HUTCHMED to Announce 2023 Final Results

2 items

Hong Kong, Shanghai & Florham Park, NJ — Thursday, February 1, 2024: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2023 on Wednesday, February 28, 2024

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 30 Jan 2024

HUTCHMED Receives ELUNATE^® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

2 items

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE® is the first oral targeted therapy approved in Hong Kong for metastatic colorectal canc

LSE RNS Announcement (PDF)HKEX Announcement (PDF)

Announcements & Press Releases, Oncology / Immunology | 11 Jan 2024

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

2 items

— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 — — NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who

HKEX Announcement (PDF)LSE RNS Announcement (PDF)

2 3 4 5 6 7 8 9

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED to Announce 2024 Final Results

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

HUTCHMED’s ELUNATE® (fruquintinib) Listed with Full Subsidy in the Hong Kong Hospital Authority Drug Formulary

HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia

HUTCHMED Reports 2024 Interim Results and Provides Business Updates

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

HUTCHMED to Announce 2024 Half-Year Financial Results

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting

HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress

HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

HUTCHMED to Announce 2023 Final Results

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK^® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS^® and TAGRISSO^® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA^® (fruquintinib)

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS^® and TAGRISSO^® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE^® (Fruquintinib) in Combination with TYVYT^® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

HUTCHMED Announces Continued Inclusion of ORPATHYS^® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces Launch by Takeda of FRUZAQLA^® (fruquintinib) in Japan

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA^® (fruquintinib) Sales by Takeda

HUTCHMED Announces that TAGRISSO^® plus ORPATHYS^® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

HUTCHMED’s ELUNATE^® (fruquintinib) Listed with Full Subsidy in the Hong Kong Hospital Authority Drug Formulary

HUTCHMED Receives ELUNATE^® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer